The p300/CBP inhibitor company
50+
Epigenetic-related targets
investigated over time by the CellCentric team
1
Drug prioritised, advanced
Inobrodib in the clinic, to treat specific cancers
p300/CBP are twin (paralogue) acetyl transferases and gene activating proteins that are known to play an important role in the progression of certain cancers.
Inobrodib is a novel drug which inhibits p300/CBP by binding to the twin proteins’ conserved bromodomain. This impacts the growth of specific types of cancer.
CellCentric’s pioneering drug is in clinical trials to evaluate its effectiveness to treat late-stage prostate cancer, haematological malignancies (blood cancers) and tumours with certain molecular drivers (over-expressing AR or MYC; or with a p300 or CBP mutation). These represent major clinical unmet needs, delivering a new therapy for patients that otherwise have few alternatives.
Team CellCentric will be at ESMO 2022, 9-13 Sept, Paris. Advancing inobrodib, first in class p300/CBP inhibitor drug, to treat specific cancers. pic.twitter.com/t88Iar9ir8
USAN have confirmed a new drug name (stem) for bromodomain inhibitors of p300/CBP. CellCentric’s inobrodib is first in class! pic.twitter.com/mTJpOEhUfH